Literature DB >> 18330509

[Long-term results following multidisciplinary treatment of localized Ewing's sarcoma in children and adolescents].

Christian Ullmann1, Jörn-Dirk Beck, Wolfgang Holter, Sabrina Petsch, Jürgen Dunst, Rolf Sauer, Gerhard G Grabenbauer.   

Abstract

PURPOSE: To identify results and prognostic factors on long-term survival and local control following treatment of localized Ewing's sarcoma. PATIENTS AND METHODS: Between 1979 and 2004, a total of 60 children and young adults with Ewing's sarcoma were treated. Patients with distant metastases at presentation (n = 6) and recurrent cases (n = 2) were excluded from this analysis. Patients were exclusively treated within ongoing national and international protocols CESS-81, CESS-86, EICESS-92, EURO-EWING-99. All patients received local irradiation with a total dose of 45-60 Gy; in addition, 41 (79%) of the patients had local surgical procedures, 27 (52%) of them with clear margins.
RESULTS: Overall survival rates at 5 and 10 years were 56% and 45%, respectively. Patients <or= 14 years at diagnosis had overall survival rates of 66% and 61% at 5 and 10 years compared to older patients with corresponding survival rates of 47% and 31%, respectively (p = 0.05). Patients with tumors of lower volume (<or= 100 ml) had significantly better survival rates at 5 and 10 years: 82% and 60% versus 42% und 39% (p = 0.03). Seven of 52 (14%) patients experienced local failure; no significant impact was noted for any of the following factors: treatment protocol, radiation dose, surgery.
CONCLUSION: Radiotherapy with and without surgery of Ewing's sarcoma is a highly effective local treatment option. It seems preferable to mutilating surgery.

Entities:  

Mesh:

Year:  2008        PMID: 18330509     DOI: 10.1007/s00066-008-1838-y

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  8 in total

1.  Role of radiation therapy in the multidisciplinary management of Ewing's Sarcoma of bone in pediatric patients: An effective treatment for local control.

Authors:  Jose Luis Lopez; Patricia Cabrera; Rafael Ordoñez; Catalina Marquez; Gema Lucia Ramirez; Juan Manuel Praena-Fernandez; Maria Jose Ortiz
Journal:  Rep Pract Oncol Radiother       Date:  2011-03-12

2.  Late effects surveillance system after childhood cancer in Germany, austria and parts of Switzerland--update 2009.

Authors:  Joanna Peeters; Johannes Meitert; Marios Paulides; Jörn D Beck; Thorsten Langer
Journal:  Strahlenther Onkol       Date:  2009-08       Impact factor: 3.621

3.  Radiation toxicity following busulfan/melphalan high-dose chemotherapy in the EURO-EWING-99-trial: review of GPOH data.

Authors:  Tobias Bölling; Uta Dirksen; Andreas Ranft; Iris Ernst; Heribert Jürgens; Normann Willich
Journal:  Strahlenther Onkol       Date:  2009-08       Impact factor: 3.621

4.  [Shoulder girdle, AC and SC joints].

Authors:  A B Imhoff
Journal:  Oper Orthop Traumatol       Date:  2014-06       Impact factor: 1.154

5.  A new modification of combining vacuum therapy and brachytherapy in large subfascial soft -tissue sarcomas of the extremities.

Authors:  Maximilian Rudert; Cornelia Winkler; Boris Michael Holzapfel; Hans Rechl; Peter Kneschaurek; Reiner Gradinger; Michael Molls; Barbara Röper
Journal:  Strahlenther Onkol       Date:  2010-03-26       Impact factor: 3.621

6.  Ewing's sarcoma of the larynx. Effective treatment with organ preservation.

Authors:  A Wygoda; T Rutkowski; D Ponikiewska; B Hejduk; K Składowski
Journal:  Strahlenther Onkol       Date:  2013-06-05       Impact factor: 3.621

7.  Second malignant neoplasms after childhood cancer in Germany--results from the long-term follow-up of the German Childhood Cancer Registry.

Authors:  Peter Kaatsch; Desiree Debling; Maria Blettner; Claudia Spix
Journal:  Strahlenther Onkol       Date:  2009-08       Impact factor: 3.621

8.  What's in a name? Intracranial peripheral primitive neuroectodermal tumors and CNS primitive neuroectodermal tumors are not the same.

Authors:  K Müller; B Diez; A Muggeri; T Pietsch; C Friedrich; S Rutkowski; K von Hoff; A O von Bueren; I Zwiener; F Bruns
Journal:  Strahlenther Onkol       Date:  2013-03-23       Impact factor: 3.621

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.